FERRANTE, MARTINA
 Distribuzione geografica
Continente #
NA - Nord America 564
EU - Europa 413
AS - Asia 177
AF - Africa 2
OC - Oceania 1
Totale 1.157
Nazione #
US - Stati Uniti d'America 557
IT - Italia 196
SG - Singapore 70
IE - Irlanda 52
SE - Svezia 52
CN - Cina 46
AT - Austria 19
DE - Germania 19
FI - Finlandia 16
IN - India 13
FR - Francia 12
UA - Ucraina 12
VN - Vietnam 10
GB - Regno Unito 9
HK - Hong Kong 8
JP - Giappone 8
BE - Belgio 7
IR - Iran 7
ID - Indonesia 6
PL - Polonia 6
CA - Canada 5
KR - Corea 4
NL - Olanda 4
CH - Svizzera 2
CZ - Repubblica Ceca 2
ES - Italia 2
MX - Messico 2
RU - Federazione Russa 2
AU - Australia 1
KW - Kuwait 1
LV - Lettonia 1
MY - Malesia 1
PK - Pakistan 1
SA - Arabia Saudita 1
SN - Senegal 1
TG - Togo 1
UZ - Uzbekistan 1
Totale 1.157
Città #
Chandler 85
Santa Clara 68
Singapore 57
Dublin 52
Torino 48
Florence 37
Turin 35
Ashburn 33
Fairfield 24
Nyköping 21
Vienna 18
Columbus 16
Beijing 14
Houston 14
Woodbridge 14
Helsinki 12
Cambridge 11
Munich 10
Princeton 10
Seattle 10
Ann Arbor 9
Wilmington 9
Medford 8
Villeurbanne 7
Washington 7
Dearborn 6
Jakarta 6
Naples 6
Redwood City 6
Rome 6
Boston 5
Brussels 5
Chennai 5
Fremont 5
Jacksonville 5
San Mateo 5
Coimbatore 4
Dong Ket 4
Hangzhou 4
Hebei 4
Hong Kong 4
Norwalk 4
Ottawa 4
Pisa 4
Chengdu 3
Mountain View 3
San Francesco 3
Seoul 3
Tokyo 3
Assago 2
Baran 2
Boardman 2
Bresso 2
Brno 2
Cocconato 2
Guadalupe 2
Guangzhou 2
Kunming 2
Monza 2
Pavia 2
Rotterdam 2
Saint Petersburg 2
San Diego 2
Syracuse 2
Tehran 2
University Park 2
Warsaw 2
Alba 1
Albuquerque 1
Amsterdam 1
Antwerpen 1
Barcelona 1
Berlin 1
Bethesda 1
Bilbao 1
Campi Bisenzio 1
Cedar Knolls 1
Central District 1
Chieri 1
College Park 1
Como 1
Dallas 1
El Sobrante 1
Falkenstein 1
Gharbi 1
Grafing 1
Görwihl 1
Hefei 1
Islamabad 1
Kalken 1
Kuala Lumpur 1
Kuwait City 1
Lappeenranta 1
Le Grand-Saconnex 1
Leawood 1
Leicester 1
Lomé 1
Los Angeles 1
Malmo 1
Milan 1
Totale 805
Nome #
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 206
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 195
Droplet Digital PCR Assay for MYD88L265P 91
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 89
New UPLC-MS/MS method for simultaneous determination of dolutegravir, elvitegravir, rilpivirine and other 14 HIV drugs in human plasma 87
Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment 79
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma 67
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma 62
Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network 61
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 49
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 48
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network 39
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up 29
Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study 26
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance 25
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia 23
Non-invasive diagnostic tools for minimal residual disease monitoring in lymphoproliferative disorders 10
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial 3
MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring: ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation 2
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study 2
Totale 1.193
Categoria #
all - tutte 4.822
article - articoli 0
book - libri 0
conference - conferenze 638
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.460


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202083 0 0 0 0 0 6 14 16 11 19 12 5
2020/2021148 24 10 18 1 14 6 0 9 12 11 13 30
2021/2022192 7 5 7 18 15 7 16 15 2 28 44 28
2022/2023299 24 39 5 26 31 75 25 13 32 2 13 14
2023/2024128 21 24 12 10 8 16 2 3 2 8 4 18
2024/2025234 4 17 24 38 107 44 0 0 0 0 0 0
Totale 1.193